Drug profile · INN
nonacog beta pegol
REFIXIA
nonacog beta pegol (REFIXIA) is a coagulation factor ix exogenous protein.
EMA: approved PMDA: approved Blood and blood forming organs (B02) B02BD04
Patents linked 0
Pipeline programs 1
News articles 0
Drug details — nonacog beta pegol
- Class
- Blood and blood forming organs (B02)
- Route
- —
- Patents
- 0
- Programs
- 1
- Data quality
- 0.83
Quick answer
nonacog beta pegol (REFIXIA) is a coagulation factor ix exogenous protein.
Key facts
INN nonacog beta pegol
Brand REFIXIA
Mechanism Coagulation factor IX exogenous protein
Target Coagulation factor IX
Therapeutic class Blood and blood forming organs (B02)
ATC code B02BD04
Mechanism of action
Coagulation factor IX exogenous protein
Primary target: Coagulation factor IX
Approval history
| Authority | Status | Date |
|---|---|---|
| EMA | approved | — |
| PMDA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is nonacog beta pegol?
nonacog beta pegol (REFIXIA) is a coagulation factor ix exogenous protein.
What is the brand name for nonacog beta pegol?
REFIXIA is a marketed brand name for nonacog beta pegol. Check FDA Drugs@FDA for the current US label holder and prescribing information.